‘A study has shown that a single dose of VaxGen’s smallpox vaccine candidate LC16m8 provides mice with 100% protection from vaccinia, a relative of the smallpox virus.

The purpose of the study, published in the Journal of Virology, was to compare the efficacy of LC16m8 with that of its parent strain, the Lister strain of vaccinia, from which it was derived.’

Read more at Positive results in study of VaxGen’s smallpox vaccine

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Wednesday, September 7th, 2005 at 4:10 am and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.